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There is ample evidence that deregulation of apopto-
sis results in the development, progression, and/or
maintenance of cancer. Since many apoptotic regula-
tory genes (e.g. bcl-x) code for alternatively spliced pro-
tein variants with opposing functions, the manipulation
of alternative splicing presents a unique way of regulat-
ing the apoptotic response. Here we have targeted oli-
gonucleotides antisense to the 5*-splice site of bcl-xL, an
anti-apoptotic gene that is overexpressed in various
cancers, and shifted the splicing pattern of Bcl-x
pre-mRNA from Bcl-xL to Bcl-xS, a pro-apoptotic splice
variant. This approach induced significant apoptosis in
PC-3 prostate cancer cells. In contrast, the same oligo-
nucleotide treatment elicited a much weaker apoptotic
response in MCF-7 breast cancer cells. Moreover, al-
though the shift in Bcl-x pre-mRNA splicing inhibited
colony formation in both cell lines, this effect was much
less pronounced in MCF-7 cells. These differences in
responses to oligonucleotide treatment were analyzed
in the context of expression of Bcl-xL, Bcl-xS, and Bcl-2
proteins. The results indicate that despite the presence
of Bcl-x pre-mRNA in a number of cell types, the effects
of modification of its splicing by antisense oligonucleo-
tides vary depending on the expression profile of the
treated cells.
Apoptosis, or programmed cell death, is a highly regulated
process controlled by numerous genes that determine a proper
response to death signals (1–4); the relative levels of expres-
sion of pro- and anti-apoptotic genes appear to be particularly
important (5–9). Deregulation of apoptosis, which contributes
to the development, progression, and/or maintenance of cancer
(3, 4, 10), is frequently caused by mechanisms that alter splic-
ing of regulatory genes (11, 12). Therefore, this work focused on
the modification of alternative splicing of bcl-x, a member of the
bcl-2 family of apoptotic genes that play crucial roles in both
inhibiting and activating the apoptotic response to cellular
insults (1, 2). Bcl-x is alternatively spliced to produce two
distinct mRNAs and two variant proteins, Bcl-xL and Bcl-xS,
that have antagonistic functions; the longer, 241-amino acid
protein (Bcl-xL) inhibits apoptosis, whereas the shorter, 178-
amino acid protein (Bcl-xS) activates it (13).
Bcl-xL is highly expressed in many types of cancers, includ-
ing multiple myeloma (14), small cell lung carcinoma (15), and
breast cancer (16). High Bcl-xL expression levels have been
associated with an increased risk of metastasis in breast cancer
(16) as well as with an increased resistance to apoptosis in-
duced by methotrexate and 5-fluorouracil (17) and etoposide
and cisplatin (18). Additionally, an immunohistochemical
study (19) showed that Bcl-x, presumably Bcl-xL, was ex-
pressed in 100% of prostate tumors and that its immunointen-
sity was stronger in higher grade metastases.
Bcl-xS antagonizes the pro-survival properties of Bcl-xL (13,
20) and appears to induce apoptosis. For example, high levels of
Bcl-xS induced apoptosis in cancer cells from patients with
colon and stomach cancers (21) as well as in human mammary
tumors in nude mice (22). However, overexpression of Bcl-xS
did not cause apoptosis in an established breast cancer cell line;
the latter cells became apoptotic only after additional treatment
with the chemotherapeutic agents Taxol and etoposide (23).
Work from this laboratory showed that antisense oligonu-
cleotides could be used to modify the splicing patterns of vari-
ous genes in cell culture (24–27). We therefore hypothesized
that blocking the alternative 59-splice site in intron 2 of Bcl-x
with an antisense oligonucleotide should shift splicing from
Bcl-xL to Bcl-xS mRNA, thereby increasing the level of pro-
apoptotic Bcl-xS protein and decreasing the level of its anti-
apoptotic isoform, Bcl-xL. We show here that this shift in splic-
ing could indeed be accomplished and that it induced apoptotic
markers in the prostate cancer cell line PC-3. However, in the
breast cancer cell line MCF-7, shifting splicing from Bcl-xL to
Bcl-xS and induction of apoptosis were much less efficient.
Differences in the responses to oligonucleotide treatment were
also evident in the inhibition of cell growth of the two cell lines.
EXPERIMENTAL PROCEDURES
Cells—PC-3 cells were cultured in Dulbecco’s modified Eagle’s medi-
um/nutrient mixture F-12 supplemented with 10% fetal calf serum.
MCF-7 cells were cultured in modified essential medium supplemented
with 10% fetal calf serum, 13 sodium pyruvate (Life Technologies, Inc.),
13 nonessential amino acids (Sigma), and 10 mg/ml insulin. Twenty-
four hours prior to oligonucleotide treatment, the cells were plated in 2
ml of medium in 6-well plates at a density of 2 3 105 cells/well. For
experiments requiring estrogen-free medium, MCF-7 cells were cul-
tured in phenol red-free medium containing 10% (4 days) and then 3%
(3 days) charcoal-stripped fetal calf serum (Hyclone Laboratories, Lo-
gan, UT) (28, 29).
Oligonucleotide Treatment—29-O-Methyl-modified oligoribonucleo-
side phosphorothioate 18-mers antisense to the 59-splice site of Bcl-xL
(59-Bcl-x AS, ACCCAGCCGCCGUUCUCC) and to the 39-splice site of
exon III in Bcl-x pre-mRNA (39-Bcl-x AS, GUUCCACAAAAGUAUCCU)
were used. Oligonucleotides with randomized and anti-b-globin se-
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quences (24) were used as negative controls. All oligonucleotides were
synthesized and purified by Hybridon, Inc. (Milford, MA) and Trilink
Biotechnologies, Inc. (San Diego, CA). The cells were treated with
oligonucleotidezDMRIE-C Reagent (8 mg/ml; Life Technologies, Inc.)
cationic lipid complexes according to the manufacturer’s directions at
the concentrations indicated on the figures. Ten hours post-treatment,
the medium was replaced with fresh medium, and the cells were cul-
tured for the indicated times. Thapsigargin (0.5 mM final concentration;
Sigma) was added directly to the medium of MCF-7 cells 24 h
post-transfection.
RNA Isolation and Reverse Transcription-Polymerase Chain React-
ion (RT-PCR)1—Oligonucleotide-treated cells were lysed in 1 ml of TRI-
reagent (Molecular Research Center, Inc., Cincinnati, OH), and total
RNA was isolated. RNA (200 ng) was used in RT-PCR with rTth enzyme
(PerkinElmer Life Sciences) in the presence of 0.2 mCi of [a-32P]dATP.
Both procedures followed the manufacturers’ protocols. The reverse
transcription reaction was carried out at 70 °C for 15 min, followed by
PCR: one cycle of 95 °C for 3 min; 22 cycles of 95 °C for 30 s, 56 °C for
30 s, and 72 °C for 1 min; and a final extension at 72 °C for 7 min. The
forward and reverse primers used were GCATTGTTCCCATAGAGT-
TCC and GCATTGTTCCCATAGAGTTCC, respectively. Under these
conditions, the linear concentration-dependent response of PCR was
maintained (data not shown). The resulting products (Bcl-xL, 300 bp;
and Bcl-xS, 162 bp) were separated on 8% nondenaturing polyacryla-
mide gels, and the gels were autoradiographed with Kodak BioMax
film. All autoradiograms were captured by a Dage-MTI CCD72 video
camera, and the images were processed using NIH IMAGE Version 1.61
software. NIH IMAGE was also used to quantify the density of the
bands. The percentage of Bcl-xS in each lane was determined by divid-
ing the intensity of the 162-bp band (Bcl-xS) by the total intensities of
the 300-bp (Bcl-xL) and 162-bp (Bcl-xS) bands. The calculations reflect
the fact that the number of radioactive adenosine nucleotides in the
Bcl-xL band is 1.2 times higher than that in the Bcl-xS band. Thus, the
percent of correction is higher than appears from the autoradiograms.
Protein Analysis—Transfected cells were harvested at the indicated
time points in radioimmune precipitation assay buffer (50 mM Tris-HCl,
150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.1% SDS, and 1% sodium
deoxycholate) and a mixture of protease inhibitors (Sigma). Total pro-
tein (100 mg for Bcl-xS, 10 mg for Bcl-xL and Bcl-2, and 75 mg for PARP)
from the cells was electrophoresed on a 15% (for Bcl-2, Bcl-xL, and
Bcl-xS) or 8% (for PARP) SDS-polyacrylamide gel and electrotrans-
ferred to polyvinylidene difluoride membranes. Equal gel loading and
transfer of protein were confirmed by staining the membranes with
Ponceau S. Membranes were blocked for 1 h with BLOTTO (5% nonfat
powdered milk in Tris-buffered saline/Tween) and incubated for 1 h at
room temperature with rabbit anti-Bcl-xL polyclonal antibody (1:1000
dilution; Transduction Laboratories, Lexington, KY), mouse anti-Bcl-2
monoclonal antibody (1:250 dilution; Transduction Laboratories), or
rabbit anti-PARP polyclonal antibody (1:1000 dilution; Cell Signaling
Technology, Beverly, MA), followed by 1 h of incubation with horserad-
ish peroxidase-conjugated anti-rabbit (1:5000 dilution; Bio-Rad) or anti-
mouse (1:1000 dilution; Amersham Pharmacia Biotech) secondary an-
tibodies. Blots were developed with ECL Plus reagents (Amersham
Pharmacia Biotech) and exposed to Kodak film. Bcl-xL, Bcl-xS, Bcl-2,
and cleaved PARP proteins migrated at ;30, 21, 26, and 89 kDa,
respectively. The densities of the resulting bands were quantified using
NIH IMAGE Version 1.61 software.
Fluorescence-activated Cell Sorting (FACS) Analysis—At the indi-
cated times after oligonucleotide treatment, cells were resuspended by
trypsinization, and aliquots were removed for RT-PCR analysis (see
above) and for colony formation assays (see below). The remaining cells
were washed twice with cold 13 phosphate-buffered saline, fixed in cold
70% ethanol, and stored at 220 °C for at least 24 h. They were then
washed with 13 phosphate-buffered saline and treated with 20 mM
propidium iodide and 1 mg/ml RNase A in 13 phosphate-buffered saline
for 30 min in the dark. Cells were analyzed by flow cytometry using a
Becton Dickinson FACSort for two measures of apoptosis: subdiploid
DNA and loss of cell volume (30–32).
Colony Formation Assay—Aliquots of trypsinized cell suspensions
were seeded on 100-mm plates at 5 3 102 for PC-3 cells and 1 3 103 for
MCF-7 cells. After 10 days under normal culture conditions, cells were
stained with 5% methylene blue (Sigma) in 50% ethanol for 10 min.
Colonies of .50 cells were counted.
Statistical Analysis—Numerical data were analyzed by one-way
analysis of variance and post hoc Student-Neuman-Keuls tests using
the statistical software program STATVIEW. The significance level for
all analyses was 5%.
RESULTS
Shift in Splicing from Bcl-xL to Bcl-xS in Oligonucleotide-
treated PC-3 Cells—PC-3 cells were treated with increasing
amounts of 59-Bcl-x AS, a 29-O-methyl-modified oligoribo-
nucleoside phosphorothioate 18-mer targeted to the down-
stream alternative 59-splice site in Bcl-x pre-mRNA. Splicing at
this site led to Bcl-xL mRNA and protein; alternative splicing at
the upstream site resulted in the Bcl-xS splice variant (Fig. 1).
The 29-O-methyl-modified oligonucleotide was chosen because
it is resistant to nucleases, does not induce degradation of RNA
in the RNA-oligonucleotide hybrid by RNase H (33), and binds
to the target sequence with high Tm (34). These properties
predict that the oligonucleotide should block the targeted splice
site and induce a shift in the splicing pathways from Bcl-xL to
Bcl-xS mRNA.
RT-PCR analysis (see “Experimental Procedures”) of total
cell RNA 24 h post-treatment showed that 59-Bcl-x AS treat-
ment led to a dose-dependent shift in splicing from the Bcl-xL to
Bcl-xS pathway as indicated by a shift in the ratios of the
respective mRNAs (Fig. 2A, upper panel, lanes 2–7). At the
highest concentrations of the 59-Bcl-x AS oligonucleotide, the
level of Bcl-xS reached ;65% of the total amount of Bcl-xS and
Bcl-xL isoforms (Fig. 2A, lower panel, lane 7). There was no
shift in Bcl-x pre-mRNA splicing in cells treated with an oligo-
nucleotide with a randomized sequence (Fig. 2A, lanes 8–11).
After a single treatment of PC-3 cells with 0.08 mM 59-Bcl-x AS
oligonucleotide, a maximal shift in splicing occurred at 12 h
post-treatment and persisted, with a slight decrease, for at
least 72 h (Fig. 2B, lanes 3–6). This decrease was presumably
due to dilution of the oligonucleotide and/or instability of the
oligonucleotide and Bcl-xS mRNA in dividing cells. As expected,
despite prolonged culture of the cells, the randomized oligonu-
cleotide had no effect on the Bcl-xL/Bcl-xS mRNA ratio (Fig. 2B,
lanes 7–11).
Since a shift in the splicing pattern of Bcl-x pre-mRNA from
Bcl-xL to Bcl-xS should change the Bcl-xL/Bcl-xS protein ratio,
we analyzed total protein from the PC-3 cell line by immuno-
blotting and probing with an antibody expected to detect both
splice variants of the Bcl-x protein. This analysis showed a
time-dependent decrease in Bcl-xL protein (Fig. 3, upper panel,
lanes 2–5) and an increase in Bcl-xS protein (lower panel, lanes
1 The abbreviations used are: RT-PCR, reverse transcription-po-
lymerase chain reaction; bp, base pair(s); PARP, poly(ADP-ribose)
polymerase; FACS, fluorescence-activated cell sorting.
FIG. 1. Alternative splicing of Bcl-x pre-mRNA. Use of the down-
stream or upstream alternative 59-splice site within exon II yields the
anti-apoptotic Bcl-xL or pro-apoptotic Bcl-xS isoform, respectively. The
thin line indicates the Bcl-xL splicing pathway, predominant in many
cancer cells. The dotted line indicates the splicing pathway for Bcl-xS
mRNA. Boxes, exons; thick lines, introns; solid black boxes, the 189-
nucleotide portion of exon II included in Bcl-xL; thick bars below the
pre-mRNA, antisense oligonucleotides. The oligonucleotide antisense to
the 59-splice site (59-Bcl-x AS), but not that antisense to the 39-splice site
(39-Bcl-x AS), of Bcl-x pre-mRNA induced a shift in splicing from Bcl-xL
to Bcl-xS.
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2–5) in cells treated with 0.08 mM 59-Bcl-x AS oligonucleotide,
but not in cells treated with the randomized oligonucleotide
(lower panel, lanes 6–9).
Apoptosis and Death of PC-3 Cells Caused by a Shift in
Splicing from Bcl-xL to Bcl-xS—To determine whether increas-
ing the levels of Bcl-xS protein increased apoptosis of 59-Bcl-x
AS oligonucleotide-treated PC-3 cells, the cells were analyzed
by FACS for two measures of apoptosis: subdiploid DNA and
loss of cell volume. As illustrated in Fig. 4A, the population of
cells that had degraded their DNA (shown in green in the left
panels and to the left of the bars in the right panels) also
exhibited a decreased cell size (lower left corners in the left
panels). Quantitation of the results of multiple experiments
showed that treatment with 0.01, 0.03, and 0.08 mM 59-Bcl-x AS
oligonucleotide resulted in 6.4, 11.2, and 19.8% of the PC-3
cells, respectively, exhibiting subdiploid DNA (Fig. 4B); the
latter result was statistically significant (p , 0.0001, analysis
of variance and Student-Neuman-Keuls tests) in comparison
with mock-treated cells (4.4%) or with cells transfected with 0.8
mM randomized oligonucleotide (5.0%). Similarly, treatment
with the 59-Bcl-x AS oligonucleotide resulted in a dose-depend-
ent loss of cell volume; at 0.08 mM 59-Bcl-x AS, the effect (20.3%)
was statistically significant (p , 0.0001) relative to either
mock-treated (5.2%) or randomized oligonucleotide-treated
(6.0%) cells (data not shown). Thus, by two different criteria
and consistent with the RT-PCR and immunoblot results, the
shift in splicing of Bcl-x pre-mRNA from Bcl-xL to Bcl-xS led to a
dose-dependent increase in apoptosis of PC-3 cells.
The ultimate goal of shifting splicing from the Bcl-xL to
Bcl-xS isoform is to induce cell death. Since it has been argued
that apoptotic markers, especially in cells with mutated p53,
underestimate the killing potential of cytotoxic drugs (35), we
have analyzed the effects of 59-Bcl-x AS treatment of PC-3 cells
on cell survival. The colony formation assay showed statisti-
cally significant cell death at 0.01, 0.03, and 0.08 mM 59-Bcl-x
AS oligonucleotide compared with mock- or randomized oligo-
nucleotide-transfected cells (Fig. 4C). At these oligonucleotide
concentrations, the number of surviving cells was reduced 2.0-,
2.6-, and 4.4-fold, respectively, relative to mock treatment and
1.7-, 1.8-, and 3.8-fold relative to randomized oligonucleotide
treatment. Thus, the long-term effects of the treatment were
even more pronounced than those detected by the short-term
assays of apoptotic markers.
Inefficient Induction of Apoptosis by Down-regulation of
Bcl-xL Pre-mRNA in PC-3 Cells—Shifting splicing of Bcl-x
pre-mRNA should presumably lead to a more efficient induc-
tion of apoptosis than down-regulation of Bcl-xL because the
former approach leads to simultaneous down-regulation of an-
ti-apoptotic Bcl-xL and up-regulation of pro-apoptotic Bcl-xS. To
test this hypothesis, PC-3 cells were treated with an oligonu-
cleotide targeted to the 39-splice site of exon III in Bcl-x
pre-mRNA (39-Bcl-x AS; see Fig. 1). In contrast to 59-Bcl-x AS,
this oligonucleotide should simultaneously decrease the level of
Bcl-xL and Bcl-xS proteins because the 39-splice site is common
to both Bcl-xL and Bcl-xS splice variants.
As predicted, at 0.08 mM, the 39-Bcl-x AS oligonucleotide led
to a decrease in the levels of Bcl-xL protein (Fig. 5A, upper
panel, lane 2). The levels of Bcl-xS protein appeared unaffected
(Fig. 5A, lower panel, lane 2) and equal to that in mock-treated
or control cells (lanes 1 and 4, respectively). In agreement with
the results shown in Fig. 3, 59-Bcl-x AS decreased Bcl-xL levels
(Fig. 5A, upper panel, lane 3), but increased Bcl-xS protein
levels (lower panel, lane 3). FACS analysis of the oligonucleo-
tide-treated cells showed that 39-Bcl-x AS was approximately
half as efficient as 59-Bcl-x AS in inducing apoptosis (Fig. 5B).
These results confirm that apoptosis of PC-3 cells is more
FIG. 2. Shift in splicing from Bcl-xL to Bcl-xS by treatment of
PC-3 cells with 5*-Bcl-x AS. The results from the analysis of total
cellular RNA by RT-PCR are shown. A: upper panel, dose dependence of
cells treated for 24 h. Lane 1, mock-transfected cells; lanes 2–7, cells
transfected with 59-Bcl-x AS; lanes 8–11, cells transfected with an
oligonucleotide with randomized sequence. The lengths of the PCR
products (in base pairs) are indicated to the right. Lower panel, quan-
titative analysis of the results. Black bar, mock-transfected cells; gray
bars, 59-Bcl-x AS oligonucleotide-transfected cells; white bars, random-
ized oligonucleotide-treated cells. B: upper panel, time course. Lane 1,
mock-transfected cells; lanes 2–6, RNA isolated from 59-Bcl-x AS oligo-
nucleotide (0.08 mM)-transfected cells 6, 12, 24, 48, and 72 h post-
transfection, respectively; lanes 7–11, cells transfected with the ran-
domized oligonucleotide (0.08 mM). Lower panel, quantitation of the
results. Designations are as the same as described for A.
FIG. 3. Western blot analysis of Bcl-x proteins from PC-3 cells
transfected with 0.08 mM 5*-Bcl-x AS. The times post-transfection
are indicated above the lanes. Upper panel, Bcl-xL protein; lower panel,
Bcl-xS protein. Lanes 2–5, cells treated with 59-Bcl-x AS; lanes 6–9, cells
treated with the randomized oligonucleotide. See “Experimental Proce-
dures” for details.
Modification of Alternative Splicing of Bcl-x Pre-mRNA 16413
efficiently induced by an increase in Bcl-xS than by a decrease
in Bcl-xL, validating the approach of modification of splicing of
Bcl-x pre-mRNA.
Shift in Splicing from Bcl-xL to Bcl-xS in MCF-7 Cells Leads
to Cell Death with Minimal Induction of Apoptosis—Since
Bcl-xL is overexpressed in ;40–60% of breast cancers (16), we
also tested the 59-Bcl-x AS oligonucleotide against a breast
cancer cell line, MCF-7. Similar to PC-3 cells, treatment of
MCF-7 cells with the oligonucleotidezDMRIE-C Reagent com-
plex resulted in a dose-dependent (Fig. 6, lanes 2–6) and
sequence-dependent (lanes 7–11) shift in Bcl-x pre-mRNA
splicing from the Bcl-xL to Bcl-xS pathway; however, the effects
were much less pronounced. At 0.1 mM oligonucleotide, only
18% of Bcl-xS was generated (compared with 62% in PC-3 cells),
and the maximal Bcl-xS level (54%) was reached at 1.0 mM
oligonucleotide, i.e. at a concentration almost 10 times higher
than that needed for PC-3 cells. As a consequence of the shift in
splicing, the level of Bcl-xL protein decreased, and that of Bcl-xS
protein increased (see Fig. 10, A and B, respectively, lane 5).
The effects of the 59-Bcl-x AS oligonucleotide persisted for up to
72 h (data not shown).
FIG. 4. Apoptosis of PC-3 cells treated with 5*-Bcl-x AS (0.08
mM) for 36 h. A, FACS analysis plots. The left panels show dot plots of
forward scatter (cell size) versus side scatter (cell granularity). Cells
that have degraded their DNA are shown in green and are smaller in
size. The right panels show the DNA histograms (with subdiploid DNA
to the left of the bars). B, quantitation of subdiploid DNA. The asterisk
indicates a statistically significant difference from mock and random-
ized oligonucleotide treatments (p , 0.0001; significance level 5 5%).
Results are from at least three independent experiments. Black bar,
mock-transfected cells; gray bars, 59-Bcl-x AS oligonucleotide-trans-
fected cells; white bars, random oligonucleotide-transfected cells. C,
inhibition of colony formation in cells treated with the 59-Bcl-x AS
oligonucleotide (p , 0.0001; significance level 5 5%). The number of
experiments and designations are the same as described for B.
FIG. 5. Inefficient induction of apoptosis in PC-3 cells by 3*-
Bcl-x AS targeted to the 3*-splice site of Bcl-x pre-mRNA. A,
Western blot analysis of Bcl-x proteins from PC-3 cells transfected for
36 h with 0.08 mM 39- and 59-Bcl-x AS oligonucleotides. Upper panel,
Bcl-xL protein; lower panel, Bcl-xS protein. Lane 1, mock-transfected
cells; lane 2, 39-Bcl-x AS oligonucleotide-treated cells; lane 3, 59-Bcl-x
AS oligonucleotide-treated cells; lane 4, randomized oligonucleotide
(0.08 mM)-treated cells. B, FACS analysis of subdiploid DNA in cells
treated for 36 h with 39- and 59-Bcl-x AS oligonucleotides. Gray bars,
treatment with 59-Bcl-x AS; hatched bars, treatment with 39-Bcl-x AS.
FIG. 6. Shift in splicing from Bcl-xL to Bcl-xS in MCF-7 cells
treated with 5*-Bcl-x AS for 24 h. Upper panel, analysis of total RNA
by RT-PCR. Lane 1, mock-transfected cells; lanes 2–6, 59-Bcl-x AS
oligonucleotide-treated cells; lanes 7–11, randomized oligonucleotide-
treated cells. Lower panel, quantitation of the results. Designations are
the same as described in the legend to Fig. 2A.
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In contrast to PC-3 cells, 59-Bcl-x AS oligonucleotide-treated
MCF-7 cells did not appear to undergo significant apoptosis.
Approximately 3.6, 5.2, and 5.2% of the cells exhibited subdip-
loid DNA (Fig. 7, left three bars) and loss of cell volume (data
not shown) when mock-transfected or transfected with the
randomized oligonucleotide or with the 59-Bcl-x AS oligonucleo-
tide, respectively. Interestingly, despite the lack of apoptotic
markers, the colony formation assay showed that the cells
transfected with the 59-Bcl-x AS oligonucleotide formed ;2.7-
fold fewer colonies than the negative control cells (Fig. 8, left
three bars).
Since the MCF-7 cells treated with 59-Bcl-x AS alone did not
exhibit subdiploid DNA or loss of cell volume, we sought to
determine if the increased Bcl-xL/Bcl-xS isoform ratio gener-
ated by the oligonucleotide treatment of the cells sensitized
them to apoptotic inducers such as thapsigargin. Thapsigargin
is known to induce apoptosis by depleting the intracellular
calcium stores without increasing the influx of extracellular
calcium (36). This mechanism was shown to be inhibited by
anti-apoptotic proteins such as Bcl-2 (37) and Bcl-xL (38) and
should be restored if the ratio of Bcl-xS to Bcl-xL and Bcl-2 were
significantly increased.
Twenty-four hours after transfection with the oligonucleo-
tide, the cells were treated with 0.5 mM thapsigargin for 48 h.
Relative to mock-transfected cells, 59-Bcl-x AS combined with
thapsigargin treatment resulted in a statistically significant
increase in the percentage of cells with subdiploid DNA (p 5
0.04) (Fig. 7, middle three bars) and loss of cell volume (data not
shown). There was no statistically significant difference be-
tween cells treated with a randomized oligonucleotide plus
thapsigargin and with the 59-Bcl-x AS oligonucleotide plus
thapsigargin.
Despite the lack of induction of apoptotic markers in 59-Bcl-x
AS oligonucleotide-treated cells, the survival of the MCF-7 cells
treated with the 59-Bcl-x AS oligonucleotide alone was consis-
tently reduced (Fig. 8, left three bars). Interestingly, the addi-
tional treatment with thapsigargin had only a minor effect, if
any, on cell survival (Fig. 8, three right bars). The difference in
cell death after treatment with Bcl-x AS alone or in combina-
tion with thapsigargin was not statistically significant.
The oligonucleotide-induced cell death without evidence of
cell apoptosis was intriguing, raising a possibility that the
apoptosis assay based on DNA fragmentation may be inade-
quate in detecting apoptosis in the MCF-7 cell line. Therefore,
we tested 59-Bcl-x AS oligonucleotide-treated PC-3 and MCF-7
cells for PARP cleavage (Fig. 9), another indicator of apoptosis.
Twenty-four hours after a single treatment with the 59-Bcl-x
AS oligonucleotide (0.08 mM for PC-3 cells and 0.4 mM for MCF-7
cells), this assay detected maximal apoptotic response of PC-3
cells, but virtually no apoptosis of MCF-7 cells. PARP cleavage
did appear in MCF-7 cells at 48 h and reached maximum levels
at 72 h post-treatment. However, even at the optimal time
points, apoptosis of PC-3 cells was 3.5-fold higher than that of
MCF-7 cells.
Factors Affecting Apoptosis of MCF-7 Cells—To gain some
insight into the mechanisms responsible for the differences in
the 59-Bcl-x AS effects on PC-3 and MCF-7 cells, we compared
the two cell lines for the levels of expression of Bcl-xL, Bcl-xS,
and Bcl-2 proteins. Fig. 10A shows that the level of Bcl-xL in
MCF-7 cells (lanes 4–6) was markedly lower than that in PC-3
cells (lanes 1–3). This suggests that even if the same Bcl-xL/
Bcl-xS mRNA ratio is induced by the oligonucleotide in the two
cell lines, the absolute amount of generated Bcl-xS protein will
be lower in MCF-7 cells. Fig. 10B (lane 5 versus 2) illustrates
this for treatment of PC-3 and MCF-7 cells with 0.08 and 0.4
mM 59-Bcl-x AS, respectively. This treatment resulted in similar
ratios of the splice variant mRNAs (data not shown). Note that
the low level of Bcl-xS protein in oligonucleotide-treated MCF-7
cells will also result in a low ratio of this protein to other
anti-apoptotic gene products.
Since a wide variety of human cancers express not only
Bcl-xL, but also Bcl-2, a potent anti-apoptotic protein whose
function is antagonized by Bcl-xS (13), the expression of Bcl-2
was assayed in the two cell lines by immunoblotting of total
protein. Densitometry of the immunoblot shown in Fig. 10C
and quantitation of the results indicated that, in MCF-7 cells,
the concentration of Bcl-2 was ;1.7 times higher than that in
PC-3 cells (compare lanes 1–3 versus 4–6). As expected, the
level of Bcl-2 was not affected by treatment of the cells with the
59-Bcl-x AS or randomized oligonucleotide (Fig. 10C, lanes 2
and 5 and lanes 3 and 6, respectively).
We have cultured MCF-7 cells in charcoal-stripped medium,
a procedure shown to remove estrogen from the medium and,
as a consequence, to inhibit expression of Bcl-2 in these cells
(28). Under these conditions, the cellular level of Bcl-2 in
MCF-7 cells was reduced below the level detected in PC-3 cells
(data not shown). However, the treatment had no effect on
apoptosis of 59-Bcl-x AS oligonucleotide-treated MCF-7 cells
(Fig. 7, right three bars). Thus, the contribution of Bcl-2 to the
induction or the lack of apoptosis in 59-Bcl-x AS oligonucleo-
tide-treated cells remains unclear.
DISCUSSION
We have taken advantage of the fact that alternative splicing
of Bcl-x pre-mRNA yields two products with antagonistic func-
tions and used an oligonucleotide antisense to the 59-splice site
FIG. 7. Apoptosis of MCF-7 cells treated with 5*-Bcl-x AS. Shown
are the results from FACS analysis for subdiploid DNA of MCF-7 cells
transfected for 24 h with 0.4 mM 59-Bcl-x AS, followed by a 48-h treat-
ment with 0.5 mM thapsigargin (Thaps). Left three bars, no thapsigargin
(72 h post-transfection); middle three bars, plus thapsigargin (48 h after
thapsigargin treatment, 72 h post-transfection); right three bars, cells
cultured in the presence of charcoal-stripped serum (CS; 72 h post-
transfection). See “Experimental Procedures” for details. The asterisk
indicates a significant difference from mock transfections (p 5 0.04;
significance level 5 5%). Black bars, mock-transfected cells; gray bars,
59-Bcl-x AS oligonucleotide-transfected cells; white bars, randomized
oligonucleotide-transfected cells.
FIG. 8. Inhibition of colony formation in MCF-7 cells treated
with 5*-Bcl-x AS (0.4 mM) as well as thapsigargin (5 mM for 48 h).
Asterisks indicate significant difference from mock- and randomized
oligonucleotide-treated cells (p 5 0.0002; significance level 5 5%). Des-
ignations are the same as described in the legend to Fig. 7. Results are
from at least three independent experiments. Thaps, thapsigargin.
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of Bcl-xL to shift splicing from the anti-apoptotic splice variant,
Bcl-xL, to the pro-apoptotic splice variant, Bcl-xS. This ap-
proach should be superior to antisense down-regulation of
Bcl-xL mRNA (39, 40) since, by definition, a decrease in Bcl-xL
leads to a concomitant increase in the concentration of the
antagonistic Bcl-xS, amplifying the biological effects of the
treatment. In fact, an oligonucleotide targeted to the 59-splice
site of Bcl-x pre-mRNA, which led to an increase in the Bcl-xS
splice variant and a decrease in the Bcl-xL splice variant, was
a better inducer of apoptosis in PC-3 cells than an oligonucleo-
tide targeted to the 39-splice site, which decreased the expres-
sion of the Bcl-xL protein.
Treatment of PC-3 and MCF-7 cells with the 59-Bcl-x AS
oligonucleotide led to a dose- and time-dependent shift in splic-
ing of Bcl-x pre-mRNA from the Bcl-xL to Bcl-xS pathway and
to a concomitant increase in the level of Bcl-xS protein. How-
ever, even though most of the Bcl-xL mRNA disappeared, the
Bcl-xL protein remained in the cells in apparent excess over the
Bcl-xS variant. There may be two reasons for this unexpected
observation. First, the anti-Bcl-x antibodies may preferentially
recognize the longer Bcl-xL polypeptide and under-represent
the Bcl-xS splice variant. This possibility seems likely since
several anti-Bcl-x antibodies from different manufacturers
failed to detect the Bcl-xS polypeptide altogether. Second, the
Bcl-xL protein may be very stable, persisting in the cells at high
concentrations even though its de novo translation was mark-
edly reduced. The latter interpretation suggests that, espe-
cially in PC-3 cells, Bcl-xS has trans-dominant properties, pro-
moting apoptosis and/or cell death despite the existing excess of
anti-apoptotic Bcl-xL. Since Bcl-xS binds to Bcl-xL and inhibits
its anti-apoptotic action (20), one has to conclude either that
the binding is not stoichiometric or that this is not the only
mechanism responsible for the pro-apoptotic properties of
Bcl-xS (20).
It appears that the minimal apoptotic response of MCF-7
cells to oligonucleotide treatment is mostly due to the low level
of Bcl-xS protein generated by the shift in the Bcl-xL/Bcl-xS
mRNA ratio. It follows that the ratio of Bcl-xS protein to other
apoptotic regulatory proteins that may impact its function may
also be lower. However, the identity and nature of the genes
that may be responsible for the apoptotic resistance of MCF-7
cells are not clear and require additional studies.
For instance, a shift in alternative splicing of Bcl-x
pre-mRNA was also observed in another breast cancer cell line,
HS578T,2 and, while this work was in progress, in a lung
adenocarcinoma cell line, A549, treated with 29-O-methoxye-
thoxy-modified oligoribonucleotides (41). Among these cell
lines, as well as the ones investigated here, the p53 gene is
mutated in PC-3 (42, 43) and HS578T (44) cells, but not in A549
(41) or MCF-7 (44) cells, and Bcl-2 is low in PC-3 (Fig. 10C) (8),
HS578T (44), and A549 (41) cells and high in MCF-7 cells (Fig.
10C) (44). Yet treatment with 59-Bcl-x AS alone led to signifi-
cant apoptosis only in PC-3 cells, whereas a decrease in Bcl-2 in
MCF-7 cells to levels below those in PC-3 cells did not promote
oligonucleotide-induced apoptosis. It appears that if the p53
and bcl-2 genes do play a role in modulating the function of the
59-Bcl-x AS oligonucleotide, their effects may depend on addi-
tional cellular background. In this regard, it is notable that
Bcl-xL was found in 100% of prostate adenocarcinomas, but
Bcl-2 was found in only 25% (19). However, in some breast
carcinomas, as well as in some breast cancer cell lines, the
levels of Bcl-2 were higher than those of Bcl-xL (45).
The different responses of PC-3 and MCF-7 cells to the shift
in Bcl-x pre-mRNA splicing are not limited to generation of
subdiploid DNA, but also to cleavage of PARP, a different
apoptotic marker, and to cell death assayed by colony forma-
tion. In this regard, 59-Bcl-x AS promoted cell death in both
PC-3 and MCF-7 cell lines, further complicating the interpre-
tation of the results. Approximately 39% of MCF-7 cells and
24% of PC-3 cells survived the treatment with 59-Bcl-x AS (0.4
mM oligonucleotide for MCF-7 cells and 0.08 mM for PC-3 cells)
that resulted in a similar ratio of Bcl-xL to Bcl-xS mRNA.
Recalculation of the data in terms of the effective concentration
(EC50) of the oligonucleotide yielded EC50 values of 0.32 and
0.05 mM for MCF-7 and PC-3 cells, respectively, a 6.5-fold ratio.
This difference is partly explained by reduced nuclear uptake of
the oligonucleotide in MCF-7 cells. In contrast to PC-3 cells, in
which fluorescent labeled oligonucleotide accumulated predom-
inantly in the nucleus, in MCF-7 cells, the large fraction of the
compound remained concentrated in cytoplasmic endosomal
vesicles (data not shown), where it was unable to affect splic-
ing, a nuclear process (46).
The fact that cells differ in their response to a shift in the
Bcl-xL/Bcl-xS ratio may impart beneficial specificity to the in
vivo applications of the 59-Bcl-x AS oligonucleotide. That is,
although Bcl-xL is expressed in a number of cell types, includ-
ing several hematopoietic cell lineages (47), the apoptotic stim-
2 D. R. Mercatante and R. Kole, unpublished data.
FIG. 9. PARP cleavage in PC-3 and MCF-7 cells treated with
5*-Bcl-x AS. Total protein from 59-Bcl-x AS oligonucleotide-treated
cells was analyzed by immunoblotting with anti-PARP antibody. The
protein samples were collected at 12, 24, and 48 h for PC-3 cells and at
24, 48, 72, and 120 h for MCF-7 cells after oligonucleotide treatment.
Band intensities were quantitated, and the results are expressed as the
level of cleavage of PARP above background generated by treatment
with the randomized oligonucleotide. Black bars, PC-3 cells (0.08 mM
59-Bcl-x AS); white bars, MCF-7 cells (0.4 mM 59-Bcl-x AS).
FIG. 10. Expression of Bcl-xL, Bcl-xS, and Bcl-2 proteins in PC-3
and MCF-7 cells. Total protein from PC-3 and MCF-7 cells was ana-
lyzed by Western blotting for Bcl-xL (A), Bcl-xS (B), and Bcl-2 (C)
proteins. Lanes 1–3, PC-3 cells subjected to mock, 59-Bcl-x AS (0.08 mM,
36 h), and randomized oligonucleotide (0.08 mM, 36 h) treatment, re-
spectively; lanes 4–6, analogous treatment (0.4 mM, 36 h) of MCF-7
cells.
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ulus of the oligonucleotide may be effective only in certain
susceptible cells with a gene expression profile akin to the
prostate cancer PC-3 cell line. In addition, a combination of the
oligonucleotide with chemotherapeutic agents exemplified by
cisplatin in A549 cells (41) may sensitize only certain types of
cells to undergo apoptosis. An additional benefit of cellular
sensitization by the oligonucleotide may be a reduction in the
dosage of chemotherapeutic agents and hence in the overall
toxicity of cancer treatment.
Acknowledgment—We thank Elizabeth Smith for excellent technical
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